1
Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia
Condition(s):Tardive DyskinesiaLast Updated:December 19, 2018Completed
Valbenazine: 21 Clinical Trials, Page 1 of 3
Hide Studies Not Open or Pending
2
Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease
Condition(s):Chorea, HuntingtonLast Updated:December 31, 2020Enrolling by invitation
3
Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia
Condition(s):Tardive Dyskinesia (TD)Last Updated:September 11, 2019Recruiting
4
The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine
Condition(s):Tardive Dyskinesia (TD)Last Updated:June 4, 2020Completed
5
Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease
Condition(s):Chorea, HuntingtonLast Updated:December 31, 2020Recruiting
6
Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
Condition(s):Tourette SyndromeLast Updated:February 17, 2020Terminated
7
Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Condition(s):Tourette SyndromeLast Updated:February 17, 2020Completed
8
Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome
Condition(s):Tourette SyndromeLast Updated:February 17, 2020Terminated
9
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Condition(s):Tourette SyndromeLast Updated:March 18, 2019Completed
10
Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of NBI-98854 in Healthy Subjects
Condition(s):Effect of Ketoconazole on the PK of NBI-98854 in Healthy SubjectsLast Updated:September 5, 2013Completed